Kinase Inhibitor
An Established Pharmacologic Class (EPC) in the FDA NDC Directory: the class FDA records for a product in its PHARM_CLASSES field.
In the NADAC file of 2026-10-14
23 products in the NADAC file of 2026-10-14 have an NDC that FDA lists in this class, covering 10 nonproprietary names as FDA writes them. 19 of them have a Medicare figure on OpenBill.
Being in one class means FDA describes the drugs’ pharmacology the same way. It does not mean one can replace another; that is a question for your prescriber.
Prices per unit: CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · as of 2026-10-14 · retrieved 2026-10-17. Classes: FDA NDC Directory · ndctext.zip · as of 2026-10-16.
The products, with what pharmacies pay per unit
- DASATINIB 100 MG TABLET
- EVEROLIMUS 0.25 MG TABLET
- EVEROLIMUS 0.5 MG TABLET
- EVEROLIMUS 0.75 MG TABLET
- EVEROLIMUS 1 MG TABLET
- EVEROLIMUS 10 MG TABLET
- EVEROLIMUS 5 MG TABLET
- IMATINIB MESYLATE 100 MG TAB
- IMATINIB MESYLATE 400 MG TAB
- KISQALI 400 MG DAILY DOSE
- KISQALI 600 MG DAILY DOSE
- NINTEDANIB ESYLATE 150 MG CAP
- OPZELURA 1.5% CREAM
- RHAPSIDO 25 MG TABLET
- SIROLIMUS 0.5 MG TABLET
- SIROLIMUS 1 MG TABLET
- SIROLIMUS 1 MG/ML SOLUTION
- SIROLIMUS 2 MG TABLET
- SPRYCEL 100 MG TABLET
- TORPENZ 10 MG TABLET
- TORPENZ 5 MG TABLET
- YULITHIRA 10 MG TABLET
- YULITHIRA 5 MG TABLET
How to read these prices
OpenBill holds every page to these five rules, written by the project’s owner and quoted word for word:
- A price is a range to expect, never a quote.
- Medicare's price is not your price. Say so on every screen that shows it.
- State which dataset and which effective date produced every figure.
- If a source is stale or a file is empty, show that rather than a zero.
- Disclaimer footer: not medical advice, no warranty, other people's data can be wrong.